Home » Insulet Earns Additional FDA Clearance for Insulin Management Systems
Insulet Earns Additional FDA Clearance for Insulin Management Systems
The FDA granted Insulet 510(k) clearance for the use of Novo Nordisk’s fast-acting insulin with its Omnipod and Omnipod DASH insulin management systems.
Fiasp (fast-acting insulin aspart) enters the patient’s bloodstream twice as fast as the company’s NovoLog product, improving glycemic control. The drug also has no pre-meal dosing recommendation.
“Omnipod can now be used with the full spectrum of insulin, from generic to branded to ultra-fast-acting, and we are thrilled to deliver this additional flexibility for people to use their insulin of choice with the Omnipod system,” said Insulet’s medical director, Trang Ly.
Upcoming Events
-
07May
-
14May
-
30May